S&P 500   5,060.35 (+1.58%)
DOW   38,884.88 (+0.71%)
QQQ   435.59 (+2.34%)
AAPL   183.27 (+0.52%)
MSFT   411.04 (+2.20%)
META   484.56 (+3.53%)
GOOGL   144.27 (+1.21%)
AMZN   172.14 (+2.11%)
TSLA   194.56 (-0.11%)
NVDA   776.33 (+15.06%)
NIO   5.81 (-2.68%)
AMD   178.09 (+8.40%)
BABA   75.41 (-0.22%)
T   16.67 (-1.94%)
F   12.20 (+0.49%)
MU   85.28 (+4.65%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.25 (+0.54%)
AMC   4.66 (+1.97%)
PFE   27.35 (-1.16%)
PYPL   57.76 (+0.49%)
XOM   103.95 (-0.86%)
S&P 500   5,060.35 (+1.58%)
DOW   38,884.88 (+0.71%)
QQQ   435.59 (+2.34%)
AAPL   183.27 (+0.52%)
MSFT   411.04 (+2.20%)
META   484.56 (+3.53%)
GOOGL   144.27 (+1.21%)
AMZN   172.14 (+2.11%)
TSLA   194.56 (-0.11%)
NVDA   776.33 (+15.06%)
NIO   5.81 (-2.68%)
AMD   178.09 (+8.40%)
BABA   75.41 (-0.22%)
T   16.67 (-1.94%)
F   12.20 (+0.49%)
MU   85.28 (+4.65%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.25 (+0.54%)
AMC   4.66 (+1.97%)
PFE   27.35 (-1.16%)
PYPL   57.76 (+0.49%)
XOM   103.95 (-0.86%)
S&P 500   5,060.35 (+1.58%)
DOW   38,884.88 (+0.71%)
QQQ   435.59 (+2.34%)
AAPL   183.27 (+0.52%)
MSFT   411.04 (+2.20%)
META   484.56 (+3.53%)
GOOGL   144.27 (+1.21%)
AMZN   172.14 (+2.11%)
TSLA   194.56 (-0.11%)
NVDA   776.33 (+15.06%)
NIO   5.81 (-2.68%)
AMD   178.09 (+8.40%)
BABA   75.41 (-0.22%)
T   16.67 (-1.94%)
F   12.20 (+0.49%)
MU   85.28 (+4.65%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.25 (+0.54%)
AMC   4.66 (+1.97%)
PFE   27.35 (-1.16%)
PYPL   57.76 (+0.49%)
XOM   103.95 (-0.86%)
S&P 500   5,060.35 (+1.58%)
DOW   38,884.88 (+0.71%)
QQQ   435.59 (+2.34%)
AAPL   183.27 (+0.52%)
MSFT   411.04 (+2.20%)
META   484.56 (+3.53%)
GOOGL   144.27 (+1.21%)
AMZN   172.14 (+2.11%)
TSLA   194.56 (-0.11%)
NVDA   776.33 (+15.06%)
NIO   5.81 (-2.68%)
AMD   178.09 (+8.40%)
BABA   75.41 (-0.22%)
T   16.67 (-1.94%)
F   12.20 (+0.49%)
MU   85.28 (+4.65%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.25 (+0.54%)
AMC   4.66 (+1.97%)
PFE   27.35 (-1.16%)
PYPL   57.76 (+0.49%)
XOM   103.95 (-0.86%)

Atea Pharmaceuticals (AVIR) Stock Forecast & Price Target

$4.17
-0.04 (-0.95%)
(As of 10:09 AM ET)

Atea Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Strong Sell
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$8.00
91.85% Upside
High Forecast$8.00
Average Forecast$8.00
Low Forecast$8.00
TypeCurrent Forecast
2/22/23 to 2/22/24
1 Month Ago
1/23/23 to 1/23/24
3 Months Ago
11/24/22 to 11/24/23
1 Year Ago
2/22/22 to 2/22/23
Consensus Rating
Strong Sell
Sell
Sell
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$8.00$6.00$6.00$6.00
Predicted Upside91.85% Upside34.41% Upside34.41% Upside13.92% Upside
Get Atea Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.


AVIR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AVIR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Atea Pharmaceuticals Stock vs. The Competition

TypeAtea PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
1.00
2.68
2.48
Consensus RatingStrong SellModerate BuyHold
Predicted Upside90.02% Upside1,098.85% Upside8.58% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:29 AM ET.












AVIR Price Target - Frequently Asked Questions

What is Atea Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Atea Pharmaceuticals stock is Sell based on the current 1 sell rating for AVIR. The average twelve-month price prediction for Atea Pharmaceuticals is $8.00 with a high price target of $8.00 and a low price target of $8.00. Learn more on AVIR's analyst rating history.

Do Wall Street analysts like Atea Pharmaceuticals more than its competitors?

Analysts like Atea Pharmaceuticals less than other Medical companies. The consensus rating for Atea Pharmaceuticals is Strong Sell while the average consensus rating for medical companies is Moderate Buy. Learn more on how AVIR compares to other companies.

Does Atea Pharmaceuticals's stock price have much upside?

According to analysts, Atea Pharmaceuticals's stock has a predicted upside of 117.39% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:AVIR) was last updated on 2/22/2024 by MarketBeat.com Staff